psilocybin – Page 3

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Development of the Japanese version of the Challenging Experience Questionnaire

mycolabadmin

Researchers have translated an important measurement tool called the Challenging Experience Questionnaire into Japanese. This tool helps doctors and researchers measure difficult feelings like fear and anxiety that people sometimes experience when taking psilocybin mushrooms as part of therapy. Having this questionnaire available in Japanese is important because it allows Japanese patients and researchers to participate in psychedelic research and understand these experiences better.

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

mycolabadmin

Two patients with severe anorexia nervosa received psilocybin-assisted therapy and unexpectedly recovered memories of sexual assault that had been unconsciously suppressed. Processing these traumatic memories with professional support led both patients to achieve remission from their eating disorders within three months. This case report suggests that psilocybin may help unlock and heal deeply buried trauma underlying eating disorders, though more research is needed to understand how this works and ensure patient safety.

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery

mycolabadmin

This study surveyed athletes and sports staff in Canada and the United States about their views on using psilocybin-assisted therapy to treat concussion symptoms. Researchers found that about 36% of athletes had used psychedelics in the past year, with psilocybin being the most common. Most athletes (61%) and staff (71%) said they would be willing to try or support psilocybin therapy for concussion recovery if research showed it was beneficial. The main factor influencing willingness was knowledge about psilocybin and positive attitudes toward it.

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

mycolabadmin

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes

mycolabadmin

This study surveyed over 250 million representative American adults about their use of psychedelic mushrooms. Researchers found that about 1.7% of US adults used psychedelic mushrooms in the past year, primarily for general mental health and well-being. Interestingly, those who used them reported higher levels of depression and anxiety, suggesting people with mental health challenges may be self-treating with mushrooms. The findings highlight the need for evidence-based guidelines as more Americans explore psychedelics for health purposes.

Are Side Effects Necessary for Antidepressive Treatment: The Psilocybin Experience

mycolabadmin

Researchers are studying psilocybin (a compound from certain mushrooms) as a potential treatment for depression. However, there is debate about whether the hallucinogenic side effects are necessary for its therapeutic benefits. This paper argues that new research suggests the antidepressant effects work through specific brain pathways (serotonin, opioid, and glutamate systems) that don’t require hallucinations. The author suggests developing safer, non-hallucinogenic antidepressants that maintain the same therapeutic benefits.

Research Topic: psilocybin